Tata Medical Center

Futó vizsgálatok

• Toboroz

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· 3. fázis· Takeda· Forrás

• Toboroz

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

  NCT07030517· 4. fázis· Johnson & Johnson Private Limited· Forrás

• Toboroz

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· 3. fázis· Takeda· Forrás

• Toboroz

  Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

  NCT06755450· 1. fázis· Aurigene Discovery Technologies Limited· Forrás

• Még nem toboroz

  Trial Comparing Avg. Global Qual of Lifescore in Hypo Frac. RT vs Conv. Frac. in H&N Cancers

  NCT06536699· Tata Medical Center· Forrás

• Fut, nem toboroz

  ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

  NCT05653063· University College, London· Forrás

• Toboroz

  A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

  NCT05984147· 1. fázis· Aurigene Discovery Technologies Limited· Forrás

• Toboroz

  A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)

  NCT05865002· 1. fázis· Aurigene Discovery Technologies Limited· Forrás

• Fut, nem toboroz

  Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

  NCT05501886· 3. fázis· Celcuity Inc· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· 3. fázis· Hoffmann-La Roche· Forrás

• Fut, nem toboroz

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· 3. fázis· Pfizer· Forrás

• Fut, nem toboroz

  A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

  NCT04988295· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

  NCT04603807· 3. fázis· Hoffmann-La Roche· Forrás

• Fut, nem toboroz

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

  NCT03165734· 3. fázis· Swedish Orphan Biovitrum· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Fej-nyaki daganatok1 toboroz
• Follikuláris limfóma1 toboroz
• Gyomor- és nyelőcsőrák1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mielóma multiplex1 toboroz
• Mieloproliferatív neopláziák1 toboroz
• Tüdőrák1 toboroz
• Vastagbélrák1 toboroz
• Vesedaganat1 toboroz

Lezárt vizsgálatok

• Lezárult

  A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

  NCT07052006· 2. fázis· Halia Therapeutics, Inc.· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· 3. fázis· Hoffmann-La Roche· Forrás

• Lezárult

  A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

  NCT05564052· 2. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

  NCT05415215· 3. fázis· Hoffmann-La Roche· Forrás

• Lezárult

  Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

  NCT04736199· 3. fázis· Bayer· Forrás

• Lezárult

  A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04182204· 3. fázis· Hoffmann-La Roche· Forrás

• Lezárult

  A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

  NCT02795988· 1/2. fázis· Imugene Limited· Forrás

• Leállították

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· 1/2. fázis· Sun Pharma Advanced Research Company Limited· Forrás

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Akut limfoid leukémia (ALL)12 munka · 1 vizsgálat
• Mielodiszplasztikus szindróma (MDS)8 munka · 2 vizsgálat